The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
| Autor: | Manoria PC; Director, Manoria Heart Care & Critical Care Hospital, Bhopal, India., Chopra HK; Sr. Consultant Cardiologist, Moolchand Medcity, New Delhi 19, India. Electronic address: drhkchopra@gmail.com., Parashar SK; Sr. Consultant Cardiologist, Metro Heart Institute, New Delhi, India., Dutta AL; Prof., Cardiology, Vivekananda Institute of Medical Sciences, Kolkata, India., Pinto B; Chief Cardiologist, Holy Family Hospital, Mumbai, India., Mullasari A; Director, Cardiology, Institute of Cardio Vascular Diseases, Madras Medical Mission, Chennai, India., Prajapati S; Medical Advisor, Cadila Healthcare, Ahmedabad, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian heart journal [Indian Heart J] 2013 Dec; Vol. 65 (6), pp. 683-90. Date of Electronic Publication: 2013 Nov 25. |
| DOI: | 10.1016/j.ihj.2013.10.015 |
| Abstrakt: | Diabetes mellitus (DM) is a pandemic disease and an important cardiovascular (CV) risk factor. The atherogenic dyslipidemia in diabetes (ADD) is characterized by high serum triglycerides, high small dense LDL levels, low HDL levels and postprandial lipemia. Insulin resistance is a primary cause for ADD. Though statins are highly effective for CVD prevention in DM but a significant residual CV risk remains even after optimal statin therapy. Fibrates, niacin and omega-3 fatty acids are used in addition to statin for treatment of ADD (specifically hypertriglyceridemia). All these drugs have some limitations and they are far from being ideal companions of statins. Many newer drugs are in pipeline for management of ADD. Dual PPAR α/γ agonists are in most advanced stage of clinical development and they have a rational approach as they control blood glucose levels (by reducing insulin resistance, a primary factor for ADD) in addition to modulating ADD. Availability of dual PPAR α/γ agnosits and other drugs for ADD management may improve CV outcomes and decrease morbidity and mortality in diabetic patients in future. (Copyright © 2013 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|